title: On the mechanisms of adenosine induced pulmonary vasoconstriction in rats.
abstract: The effect of adenosine on pulmonary vessels was studied in isolated perfused rat lungs. Drugs were administered intra-arterially in a fixed volume of 0.1 ml Krebs solution as bolus injections. Adenosine responses were obtained before and 10 min after drug injections. When applied in logarithmically increasing doses (1-100 micrograms/ml), adenosine caused dose-dependent increases in pulmonary perfusion pressure (e.g. pulmonary vasoconstriction) which were readily reversible. Challenging adenosine with quinidine, dihydroergocristine and cyproheptadine (2 micrograms/ml each) did not significantly alter adenosine responses. Pretreatment of lungs with 0.5 mM theophylline, 10 micrograms/ml indomethacin, 30 micrograms/ml tebokan (a PAF antagonist) or 1 microgram/ml methylene blue for 10 min, however, antagonized the vasoconstrictor effect of the drug significantly. From these experiments, it was concluded that the mechanisms underlying the pulmonary vasoconstrictor action of adenosine are complex, and that both types of purinoceptors, prostaglandins, PAF and other vascular endothelial hormones might be involved.
authors.affiliation: Department of Pharmacology, Istanbul University, Cerrahpaşa Medical Faculty, Istanbul, Turkey.
authors.forename: C
authors.initials: C
authors.lastname: Küçükhüseyin
authors.forename: C
authors.initials: C
authors.lastname: Silan
authors.forename: N
authors.initials: N
authors.lastname: Akbaş
authors.forename: M
authors.initials: M
authors.lastname: Payat
authors.forename: H
authors.initials: H
authors.lastname: Oncel
authors.forename: A
authors.initials: A
authors.lastname: Barlas
mesh_terms: D000241:Adenosine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D018674:Adrenergic Antagonists; D000818:Animals; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D003533:Cyproheptadine / Q000494:pharmacology; D004088:Dihydroergotoxine / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology; D005260:Female; D005419:Flavonoids / Q000494:pharmacology; D020441:Ginkgo biloba; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D008751:Methylene Blue / Q000494:pharmacology; D010936:Plant Extracts; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors; D011651:Pulmonary Artery / Q000187:drug effects* / Q000502:physiology; D058915:Purinergic P1 Receptor Antagonists; D058919:Purinergic P2 Receptor Antagonists; D011802:Quinidine / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013806:Theophylline / Q000494:pharmacology; D014661:Vasoconstriction / Q000187:drug effects* / Q000502:physiology; D000096983:Ginkgo Extract
chemical_list: D000241:Adenosine; D018674:Adrenergic Antagonists; D016861:Cyclooxygenase Inhibitors; D003533:Cyproheptadine; D004088:Dihydroergotoxine; D005419:Flavonoids; D007213:Indomethacin; D008751:Methylene Blue; D010936:Plant Extracts; D010972:Platelet Activating Factor; D058915:Purinergic P1 Receptor Antagonists; D058919:Purinergic P2 Receptor Antagonists; D011802:Quinidine; D013806:Theophylline; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract